HCV or HBV coinfection and lymphoma risk in people living with HIV.

OBJECTIVE Chronic hepatitis C virus (HCV) and hepatitis virus (HBV) infections are associated with increased risks of lymphomas in the non-HIV setting. Their impacts on HIV-associated lymphomas deserved further studies in the modern combined antiretroviral therapy (cART) era. DESIGN We evaluated the associations between HCV, HBV and HIV-related lymphomas in the Lymphovir-ANRS-CO16 cohort. METHODS Prevalence of HCV-seropositivity and chronic HBV infections were compared to those observed in the French Hospital Database on HIV (FHDH-ANRS-CO4). RESULTS Between 2008 and 2015, 179 patients with HIV-related lymphomas from 32 French hospitals were enrolled, 69 had Hodgkin's lymphoma (HL) (39%), and 110 non-Hodgkin's lymphoma (NHL) (61%). The prevalence of HCV infection was higher in patients with NHL than in the FHDH-ANRS-CO4 (26% versus 14%, Odd-Ratio (OR): 2.15; 95% confidence interval [1.35-3.32]) while there was no association between HL and chronic HCV infection. Chronic HBV infection was not associated with NHL in our cohort with a prevalence of 5% versus 7% in FHDH-ANRS-CO4 but tended to be associated with HL (prevalence of 14%, OR: 2.16 [0.98-4.27]). Chronic HCV infection tended to pejoratively impact 2-year overall survival in patients with NHL: 72% [57%, 91%] versus 82% [74%, 91%], Hazard-ratio: 2.14 [0.95-4.84]. In contrast, chronic HBV infection did not correlate with outcome. CONCLUSIONS In the modern cART era, chronic HCV infection is associated with an increased risk of NHL in PLWHIV and tends to pejoratively impact overall survival. HBV infection is not associated with the risk of NHL but with a borderline increase of HL risk.

[1]  A. Federico,et al.  Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large B‐cell non‐Hodgkin's lymphoma , 2018, Hepatology.

[2]  D. Costagliola,et al.  Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era , 2017, AIDS.

[3]  Thomas Filleron,et al.  Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Antinori,et al.  Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. , 2017, Annals of internal medicine.

[5]  R. Bruno,et al.  Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. , 2016, Blood.

[6]  T. Molina,et al.  In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas , 2016, PloS one.

[7]  A. Carbone,et al.  A lymphomagenic role for HIV beyond immune suppression? , 2016, Blood.

[8]  L. Sokol,et al.  Hepatitis B seropositivity and risk of developing multiple myeloma or Hodgkin lymphoma: A meta-analysis of observational studies. , 2015, Leukemia research.

[9]  D. Costagliola,et al.  High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  É. Oksenhendler,et al.  Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000 , 2015, PloS one.

[11]  T. Molina,et al.  Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study , 2015, American journal of hematology.

[12]  B. Autran,et al.  Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure , 2015, Gut.

[13]  C. Katlama,et al.  Cohort Profile Cohort Profile : French hospital database on HIV ( FHDH-ANRS CO 4 ) , 2014 .

[14]  M. Hleyhel Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort , 2014, AIDS.

[15]  X. Tan,et al.  Association between infection of hepatitis B virus and onset risk of B-cell non-Hodgkin’s lymphoma: a systematic review and a meta-analysis , 2014, Medical Oncology.

[16]  D. Costagliola,et al.  Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Mims,et al.  Effect of Immune Reconstitution on the Incidence of HIV-Related Hodgkin Lymphoma , 2013, PloS one.

[18]  M. Hansmann,et al.  Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. , 2013, Journal of hepatology.

[19]  D. Costagliola,et al.  Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients During the Combined Antiretroviral Therapy Era: An ANRS CO16 LYMPHOVIR Cohort Study , 2013, Journal of acquired immune deficiency syndromes.

[20]  É. Oksenhendler,et al.  The spectrum of malignancies in HIV‐infected patients in 2006 in France: The ONCOVIH study , 2011, International journal of cancer.

[21]  J. Goedert,et al.  Cancer burden in the HIV-infected population in the United States. , 2011, Journal of the National Cancer Institute.

[22]  F. Marcucci,et al.  Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. , 2011, Blood.

[23]  S. Jee,et al.  Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. , 2010, The Lancet. Oncology.

[24]  Richard D Moore,et al.  Immunologic and Virologic Predictors of AIDS-Related Non-Hodgkin Lymphoma in the Highly Active Antiretroviral Therapy Era , 2009, Journal of acquired immune deficiency syndromes.

[25]  M. Guiguet,et al.  Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. , 2009, The Lancet. Oncology.

[26]  S. Cole,et al.  A Meta-Analysis of the Incidence of Non-AIDS Cancers in HIV-Infected Individuals , 2009, Journal of acquired immune deficiency syndromes.

[27]  A. Mocroft,et al.  Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study , 2009, Antiviral therapy.

[28]  A. Hatzakis,et al.  Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Wei Wang,et al.  Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals , 2008, The Journal of experimental medicine.

[30]  J. Cerhan,et al.  Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  M. Battegay,et al.  Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study , 2007, Antiviral therapy.

[32]  N. Probst-Hensch,et al.  Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort Study , 2006, British Journal of Cancer.

[33]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[34]  P. Gaulard,et al.  Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Mocroft,et al.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort , 2005, AIDS.

[36]  X. Mariette,et al.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. , 2002, The New England journal of medicine.

[37]  S. Pol,et al.  LACK OF ASSOCIATION BETWEEN HCV INFECTION AND HIV‐RELATED LYMPHOMA , 1999, British journal of haematology.

[38]  L. Bernstein,et al.  Lack of association between hepatitis C infection and development of AIDS-related lymphoma. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.